Summary
The pharmacokinetics and haemodynamic effects of nifedipine were studied in 5 patients on long term haemodialysis. In addition, clearance of the drug on 2 different types of artificial kidneys were measured in vitro. Nifedipine was administered intravenously (1.3 mg/h) from 6 hours before starting haemodialysis to the end of haemodialysis, performed according to the standard protocol of each patient. Before and during haemodialysis, blood samples were taken for determination of free and total plasma nifedipine concentrations. Recovery was determined by measuring nifedipine concentrations in the dialysate. Heart rate and systolic and diastolic blood pressures were determined serially. The haemodynamic changes during nifedipine were compared with those of 3 previous dialysis sessions.
Haemodialysis was accompanied by a slight decrease in steady-state nifedipine concentrations. The recovery in dialysate varied between 0.6 and 0.9% of the amount infused during the period of dialysis. Artificial kidney clearance of nifedipine varied between 2.8 and 8.3 ml/min, which was in agreement with in vitro data.
Changes in steady-state nifedipine concentrations were most likely due to changes in systemic clearance caused by haemodialysis itself. Systolic and diastolic blood pressure dropped by approximately 15% and 25%, respectively, in comparison with dialysis without nifedipine, but changes in heart rate were not different. It is concluded that nifedipine is poorly dialysable. During haemodialysis, blood pressure is markedly reduced but dose schedules need not to be changed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoki K, Kondo S, Mochizuki A, Yoshida I, Kato SUK. Antihypertensive effect of cardiovascular Ca2+ antagonists in hypertensive patients in the absence and presence of beta adrenergic blockade. American Heart Journal 96: 218–226, 1978
Barr AJ, Goodnight JH, Sall JP, Blair WH, Chilko DM. In Statistical analysis system, SAS Institute Inc, Raleigh 1979
Gibson TP, Nelson HA. Drug kinetics and artificial kidneys. Clinical Pharmacokinetics 2: 403–426, 1977
Gibson TP, Matusik E, Nelson LD, Briggs WA. Artificial kidneys and clearance calculations. Clinical Pharmacology and Therapeutics 20: 720–726, 1977
Gwilt PR, Perrier D. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clinical Pharmacology and Therapeutics 24: 154–161, 1978
Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacology and Therapeutics 16: 143–166, 1982
Horsier FA, Duhm B, Maul W, Medenwald H, Patschke K, et al. Klinische Untersuchungen zur Pharmakokinetik von radioaktif markierten 4-(2-Nitrophenyl)-2,6 dimethyl-1,4-dihydropyridin-3,5-dicarbonsüre-dimethyl-ester. Arzneimittel-Forschung 22: 330–334, 1972
Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics 35: 742–749, 1984a
Kleinbloesem CH, Van Harten J, Van Brummelen P, Breimer DD. Liquid Chromatographic determination of nifedipine in plasma and of its main metabolite in urine. Journal of Chromatography Biomedical Applications 308: 209–216, 1984b
Kleinbloesem CH, Van Harten J, De Leede LGJ, Van Brummelen P, Breimer DD. Kinetics and haemodynamics of nifedipine during rectal infusion to steady-state with an osmotic system. Clinical Pharmacology and Therapeutics 36: 396–401, 1984c
Kleinbloesem CH, Van Brummelen P, Van Harten J, Danhof M, Breimer DD. Nifedipine: influence of renal function on pharmacokinetic/haemodynamic relationship. Clinical Pharmacology and Therapeutics 37: 563–574, 1985
Krebs R, Graefe KH, Ziegler R. Effects of calcium entry antagonists in hypertension. Clinical and Experimental Hypertension — Theory and Practice 4: 271–284, 1982
Kubo K, Shiraishi K, Muto H, Suzuki T, Sugino N. Treatment of hypertension in hemodialysis patients with nifedipine. Hypertension 5 (Suppl. II): 109–112, 1983
Kusano E, Asano Y, Takeda K, Matsumoto Y, Ebihara A, et al. Hypotensive effect of nifedipine in hypertensive patients with chronic renal failure. Arzneimittel-Forschung 32: 1575–1580, 1982
Kusano E, Asaro Y, Takeda K, Terao N, Hosoda S. Acute and chronic hypotensive effects of nifedipine and niludipine in hypertensive patients with chronic renal failure. Arzneimittel-Forschung 34: 624–629, 1984
McGrath BP, Tiller PJ, Bune A, Chalmers JP, Korner PI, et al. Autonomic blockade and the Valsalva manoeuvre in patients on maintenance hemodialysis: a hemodynamic study. Kidney International 13: 294–302, 1977
Rämsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 5 (Suppl. II): 18–24, 1983
Rosenkranz H, Schlossmann K, Scholtan W. Die Bindung von 4-(2′nitrophenyl)-2, 6 dimethyl-1, 4-dihydropyridin-3, 5-dicarbonsäuredimethyl ester-(nifedipine) sowie von anderen Koronar wirksamen Stoffen an die Eiweiskörper des Serums. Arzneimittel-Forschung 24: 455–466, 1974
Wagner JG. Fundamentals of clinical pharmacokinetics, Drug Intelligence Publications, Hamilton III, 1975
Wehle B, Asaby H, Castenfors J, Fürst P, Gunnarson B, et al. Hemodynamic changes during sequential ultrafiltration and dialysis. Kidney International 15: 411–418, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kleinbloesem, C.H., van Brummelen, P., Woittiez, A.J. et al. Influence of Haemodialysis on the Pharmacokinetics and Haemodynamic Effects of Nifedipine During Continuous Intravenous Infusion. Clin-Pharmacokinet 11, 316–322 (1986). https://doi.org/10.2165/00003088-198611040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198611040-00004